TCGA-NK-A5CR-01A-11R-A26W-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V2+0.460
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V1+0.420
- WNT_BETA_CATENIN_SIGNALING+0.420
- MTORC1_SIGNALING+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- DNA_REPAIR+0.280
- GLYCOLYSIS+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.730
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.530
- COMPLEMENT-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.380
- COAGULATION-0.320
- MYOGENESIS-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- ANGIOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.935 |
| 2 | TCGA-94-A5I6-01A-21R-A27Q-07 | — | cohortSQ2 | 0.919 |
| 3 | C3N-04155 | — | cohortSQ2 | 0.913 |
| 4 | TCGA-18-5595-01A-01R-1635-07 | — | cohortSQ2 | 0.908 |
| 5 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.906 |
| 6 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.896 |
| 7 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.892 |
| 8 | TCGA-DQ-5629-01A-01R-1873-07 | — | — | 0.890 |
| 9 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.888 |
| 10 | SRR8392895 | — | cohortSQ2 | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |